Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 1997

View Archived Issues

HMR and Andrx agree to stipulation in Cardizem CD patent lawsuit

Gliatech awarded SBIR grant to clone H3 receptor

Sequana receives Phase I SBIR grant for RAMMP technology

FK-037, a beta-lactam with potent activity against MRSA

Vistide launched in Germany

Potential agent for hepatitis enters clinical trials at Bristol-Myers Squibb

Fujisawa prepares novel antileukotriene agents

New isooxacephems from Roche

Cyclic peptide antifungal/antiparasitic agents disclosed by Lilly

NIH contemplates licensing liposomal delivery technology to Biovector Therapeutics

Merck & Co. focuses on farnesyltransferase inhibitors

Natural antifungal agent discovered at Merck & Co.

Spotlight on drugs for treatment of picornavirus

Leukotriene antagonists useful for asthma claimed by Bayer

Abbott describes synthesis and evaluation of novel erythromycin derivatives

P&G presents new quinolonyl-lactams

Millennium and Lilly extend cardiovascular research collaboration

Carboxyfullerenes as neuroprotective agents

Empi's new incontinence device approved by FDA; worldwide launch slated for January

Abbott presents new ketolides based on TE-802

Synthesis and biological evaluation reported for quinolonyl-carbacephems

NTZ: a potential new anti-H. pylori agent

Therapeutic Antibodies' CytoTAb enters clinical trials

ViroPharma evaluates pleconaril in phase II

Epimmune issued U.S. patent for cancer therapeutic

Knoll receives FDA approval for Vicoprofen

Sertraline alleviates symptoms in severe premenstrual syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...